AbbVievsMetagenomi Therapeutics

ABBV and MGX stock compared: price, dividend, valuation and results, from SEC filings.

MGX

Metagenomi Therapeutics, Inc.

$0.68

Value $26M

-1.73%
MGX's page

AbbVie (ABBV) has a market value of $521B and Metagenomi Therapeutics (MGX) $26M. Over the last year, with dividends, ABBV moved +30.6% and MGX -60.9%. Dividend yield: ABBV 2.35%, MGX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$521B

    MGX$26M

    ABBV is 20,359 times MGX

  • Revenue, 12 months

    ABBV$66.0B

    MGX$7.1M

    ABBV is 9,316 times MGX

  • Net income, 12 months

    ABBV$10.3B

    MGX-$94M

  • Operating margin

    ABBV32.2%

    MGX-1,410.6%

    1,442.8 points apart

  • ROIC

    ABBV25.7%

    MGX-58.0%

    83.7 points apart

  • P/E

    ABBV50.6

    MGX–

  • Dividend yield

    ABBV2.4%

    MGX0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+30.6%

MGX-60.9%

50100DecFebAprJunAugOct
Returns by period
PeriodABBVWith dividendsMGXWith dividends
1 year since November 14, 2025+30.6%Price +26.8%-60.9%Price -60.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieMGXMetagenomi Therapeutics

Valuation

ABBVMGX
Valuation
Price$294.55$0.68
Market value$521B$26M
Enterprise value (EV)$591B–
P/E50.6–
P/E, 5-year median57.0–
P/B–0.3
EV/EBIT27.8–
Free cash flow yield3.6%–

Results and growth

ABBVMGX
Results and growth
Revenue, 12 months$66.0B$7.1M
Net income, 12 months$10.3B-$94M
Free cash flow, 12 months$18.9B-$84M
Earnings per share, 12 months$5.81-$2.50
Revenue growth, year on year8.6%-51.8%
Revenue growth a year, past+5.9%over 5 years-25.0%over 2 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVMGX
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%-1,410.6%
Net margin15.7%-1,329.3%
ROIC25.7%-58.0%
ROE–-69.2%

Balance sheet

ABBVMGX
Balance sheet
Cash$10.8B$102M
Total debt$80.9B$36M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVMGX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or MGX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Metagenomi Therapeutics?

By market value, AbbVie ($521B) is about 20,358.7 times Metagenomi Therapeutics ($26M), at today's prices.

How did ABBV and MGX stock do over the last 1 years?

Since November 14, 2025, ABBV's price moved +26.8% and MGX's -60.9%. With dividends: ABBV +30.6% (+30.6% a year), MGX -60.9% (-60.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or MGX?

The dividend yield at today's price is 2.35% for AbbVie and none for Metagenomi Therapeutics. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Metagenomi Therapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and -1,329.3% for Metagenomi Therapeutics, and the operating margin 32.2% and -1,410.6%. Revenue was $66.0B and $7.1M.

Which is the better investment, AbbVie or Metagenomi Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.